FIG. 1



30000
20000
10000
0
RLU
0 0.64 3.2 16 80 400 2000 10000
Concentration of RVNA (ng/mL)
3D11E3
3H10D3
5A1C10
6F11C1
7G11A3

FIG. 2




FIG. 3A



Binding curves of 3D11E3 to RV glycoprotein which was treated by different methods
15000
10000
5000
0
RLU
0 0.64 3.2 16 80 400 2000 10000
Concentration of anti-rabies mAb (ng/mL)
1%Triton
1%Triton+0.1%SDS
1%Triton+0.1%SDS +0.05%ME

FIG. 3B



Binding curves of 3H10D3 to RV glycoprotein which was treated by different methods
60000
45000
30000
15000
0
RLU
0 0.64 3.2 16 80 400 2000 10000
Concentration of anti-rabies mAb (ng/mL)
1%Triton
1%Triton+0.1%SDS
1%Triton+0.1%SDS +0.05%ME

FIG. 3C



Binding curves of 5A1C10 to RV glycoprotein
which was treated by different methods
32000
24000
16000
8000
0
RLU
0 0.64 3.2 16 80 400 2000 10000
Concentration of anti-rabies mAb (ng/mL)
1%Triton
1%Triton+0.1%SDS
1%Triton+0.1%SDS
+0.05%ME

FIG. 3D



Binding curves of 6F11C1 to RV glycoprotein
which was treated by different methods
35000
28000
21000
14000
7000
0
RLU
0 0.64 3.2 16 80 400 2000 10000
Concentration of anti-rabies mAb (ng/mL)
1%Triton
1%Triton+0.1%SDS
1%Triton+0.1%SDS
+0.05%ME

FIG. 3E



Binding curves of 7G11A3 to RV glycoprotein which was treated by different methods
RLU
4500
3600
2700
1800
900
0
0
0.64
3.2
16
80
400
2000
10000
Concentration of anti-rabies mAb (ng/mL)
1%Triton
1%Triton+0.1%SDS
1%Triton+0.1%SDS +0.05%ME

FIG. 4A



YN1 (human)
Survival (%)
100
75
50
25
0
5
10
15
20
Days after treatment
Control
6F11C1
3H10D3
5A1C10
7G11A3
3D11E3

FIG. 4B



DRV (deer)
Survival (%)
100
75
50
25
0
5
10
15
20
Days after treatment
Control
6F11C1
3H10D3
5A1C10
7G11A3
3D11E3

FIG. 4C



HN35 (human)
Survival (%)
100
75
50
25
0
5
10
15
20
Days after treatment
Control
6F11C1
3H10D3
5A1C10
7G11A3
3D11E3

FIG. 4D



SC-CD09 (dog)
Survival (%)
100
75
50
25
0
5
10
15
20
Days after treatment
Control
6F11C1
3H10D3
5A1C10
7G11A3
3D11E3

FIG. 4E



GN07 (dog)
Survival (%)
100
75
50
25
0
5
10
15
20
Days after treatment
Control
6F11C1
3H10D3
5A1C10
7G11A3
3D11E3

FIG. 4F



ZJ-HZ09 (dog)
Survival (%)
100
75
50
25
0
5
10
15
20
Days after treatment
Control
6F11C1
3H10D3
5A1C10
7G11A3
3D11E3

FIG. 4G



BD06 (dog)
Survival (%)
100
75
50
25
0
5
10
15
20
Days after treatment
Control
6F11C1
3H10D3
5A1C10
7G11A3
3D11E3

FIG. 4H



JX08-45 (badger)
Survival (%)
100
75
50
25
0
5
10
15
20
Days after treatment
Control
6F11C1
3H10D3
5A1C10
7G11A3
3D11E3

FIG. 4I



JX09-27 (badger)
Survival (%)
100
75
50
25
0
5
10
15
20
Days after treatment
Control
6F11C1
3H10D3
5A1C10
7G11A3
3D11E3

FIG. 4J



ZJ-LA (badger)
Survival (%)
100
75
50
25
0
5
10
15
20
Days after treatment
Control
6F11C1
3H10D3
5A1C10
7G11A3
3D11E3

FIG. 5A



Competitive binding of 3D11E3-HRP to RV glycoprotein
Binding rate (%)
150
100
50
0
0 0.064 0.32 1.6 8.0 40 200 1000
Concentration of RVNA (ng/ml)
3D11E3
3H10D3
5A1C10
6F11C1
7G11A3

FIG. 5B



Competitive binding of 3D11E3-HRP to RV glycoprotein
Binding rate (%)
150
100
50
0
0 1.6 8.0 40 200 1000 5000 25000
Concentration of RVNA (ng/ml)
3D11E3
3H10D3
5A1C10
6F11C1
7G11A3

FIG. 5C



Competitive binding of 3D11E3-HRP to RV glycoprotein
Binding rate (%)
150
100
50
0
0 1.6 8.0 40 200 1000 5000 25000
Concentration of RVNA (ng/ml)
3D11E3
3M10D3
6A1C10
6F11C1
7G11A3
Irrelevant Ab
C1

FIG. 5D



Competitive binding of 3M10D3-HRP to RV glycoprotein
Binding rate (%)
150
100
50
0
0 0.064 0.32 1.6 8.0 40 200 1000
Concentration of RVNA (ng/ml)
3D11E3
3M10D3
6A1C10
6F11C1
7G11A3

FIG. 5E



Competitive binding of 3H10D3-HRP to RV glycoprotein
Binding rate (%)
200
150
100
50
0
0
1.6
8.0
40
200
1000
5000
25000
Concentration of RVNA (ng/ml)
3D11E3
3H10D3
5A1C10
6F11C1
7G11A3

FIG. 5F



Competitive binding of 3H10D3-HRP to RV glycoprotein
Binding rate (%)
150
100
50
0
0
1.6
8.0
40
200
1000
5000
25000
8
Concentration of RVNA (ng/ml)
3D11E3
3H10D3
5A1C10
6F11C1
7G11A3
Irrelevant Ab

FIG. 5G



Competitive binding of 5A1C10-HRP to RV glycoprotein
Binding rate (%)
150
100
50
0
0 0.064 0.32 1.6 8.0 40 200 1000
Concentration of RVNA (ng/ml)
3D11E3
3H10D3
5A1C10
6F11C1
7G11A3

FIG. 5H



Competitive binding of 5A1C10-HRP to RV glycoprotein
Binding rate (%)
200
150
100
50
0
0 1.6 8.0 40 200 1000 5000 25000
Concentration of RVNA (ng/ml)
3D11E3
3H10D3
5A1C10
6F11C1
7G11A3

FIG. 5I



Competitive binding of 5A1C10-HRP to RV glycoprotein
Binding rate (%)
150
100
50
0
0 1.6 8.0 40 200 1000 5000 25000
Concentration of RVNA (ng/ml)
3D11E3
3H10D3
5A1C10
6F11C1
7G11A3
Irrelevant Ab

FIG. 5J



Competitive binding of 6F11C1-HRP to RV glycoprotein
Binding rate (%)
150
100
50
0
0 0.064 0.32 1.6 8.0 40 200 1000
Concentration of RVNA (ng/ml)
3D11E3
3H10D3
5A1C10
6F11C1
7G11A3

FIG. 5K



Competitive binding of 6F11C1-HRP to RV glycoprotein
Binding rate (%)
100
75
50
25
0
0
1.6
8.0
40
200
1000
5000
25000
8
Concentration of RVNA (ng/ml)
3D11E3
3H10D3
5A1C10
6F11C1
7G11A3

FIG. 5L



Competitive binding of 6F11C1-HRP to RV glycoprotein
Binding rate (%)
150
100
50
0
0
1.6
8.0
40
200
1000
5000
25000
8
Concentration of RVNA (ng/ml)
3D11E3
3H10D3
5A1C10
6F11C1
7G11A3
Irrelevant Ab

FIG. 5M



Competitive binding of 7G11A3-HRP to RV glycoprotein
Binding rate (%)
150
100
50
0
0 0.064 0.32 1.6 8.0 40 200 1000
Concentration of RVNA (ng/ml)
3D11E3
3H10D3
5A1C10
6F11C1
7G11A3

FIG. 5N



Competitive binding of 7G11A3-HRP to RV glycoprotein
Binding rate (%)
100
75
50
25
0
0 1.6 8.0 40 200 1000 5000 25000 8
Concentration of RVNA (ng/ml)
3D11E3
3H10D3
5A1C10
6F11C1
7G11A3

FIG. 5O



Competitive binding of 7G11A3-HRP to RV glycoprotein
Binding rate (%)
150
100
50
0
0
1.6
8.0
40
200
1000
5000
25000
Concentration of RVNA (ng/ml)
3D11E3
3H10D3
5A1C10
6F11C1
7G11A3
Irrelevant Ab

FIG. 6A



A
50 μg/dose 7G11A3 and vaccine
RVNA titer (IU/ml)
100
10
1
0.1
0.01
1
3
7
14
28
Days after treatment

FIG. 6B



B
50 μg/dose 3D11E3 and vaccine
RVNA titer (IU/ml)
100
10
1
0.1
0.01
1
3
7
14
28
Days after treatment

FIG. 6C



C
50 μg/dose 3H10D3 and vaccine
RVNA titer (IU/ml)
100
10
1
0.1
0.01
1
3
7
14
28
Days after treatment

FIG. 6D



D
20 IU/kg HRIG and vaccine
RVNA titer (IU/ml)
100
10
1
0.1
0.01
1
3
7
14
28
Days after treatment

FIG. 6E



E
Vaccine
RVNA titer (IU/ml)
100
10
1
0.1
0.01
1
3
7
14
28
Days after treatment

FIG. 7



Percent survival
100
80
60
40
20
0
0
4
8
12
16
20
24
28
Days
RVNA/Vac-24h
HRIG/Vac-24h
Vac-24h
RVNA/Vac-72h
HRIG/Vac-72h
Vac-72h
Untreated

FIG. 8



SalI
FspI
SpeI
CMV promoter
VH
HindIII
beta lactamase
CH1
pUC ori
BamHI
hinge
SV40 poly(A) site
Expression Vector
CH2
CH3
ApaI
EagI
gpt
SalI
CMV promoter
SV40 promoter
VL
NheI
CL
EcoRI

FIG. 9



Lane
1
2
3
4
5
H

FIG. 10



Rabipur® ELISA Binding
OD405nm
1.0
0.8
0.6
0.4
0.2
0.0
0.1
1
10
100
1000
10000
Antibody concentration (ng/ml)
Ch1A9
Hu1A9-1
Hu1A9-2

FIG. 11



SalI
FspI
SpeI
CMV promoter
VH
HindIII
beta lactamase
CH1
pUC ori
BamHI
hinge
SV40 poly(A) site
Expression Vector
CH2
CH3
ApaI
EagI
gpt
SalI
CMV promoter
SV40 promoter
VL
NheI
CL
EcoRI

FIG. 12



Lane
1
2
3
4
5
H
L

FIG. 13



Binding of 7G11A3 1H5 to Rapibur®
Competitor
IC50
Ch2G11
0.11 μg/ml
Hu2G11-1
0.20 μg/ml
Hu2G11-2
0.23 μg/ml
Absorbance
0.4
0.3
0.2
0.1
0.0
0.001
0.01
0.1
1
10
100
Concentration of Competitor Antibody
(μg/ml)

FIG. 14A




FIG. 14B




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D




FIG. 15E




FIG. 15F




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 16E




FIG. 16F




FIG. 16G




FIG. 16H




FIG. 16I




FIG. 16J




FIG. 17A




FIG. 17B




FIG. 17C




FIG. 17D




FIG. 17E




FIG. 17F




FIG. 18A




FIG. 18B




FIG. 19




1) 5000 IU/kg RVNA cocktail and Vaccine
2) 1000 IU/kg RVNA cocktail and Vaccine
3) 200 IU/kg RVNA cocktail and Vaccine
4) 20 IU/kg HRIG and Vaccine
5) Only Vaccine
6) Negative control
RVNA titer (IU/ml)
1000
100
10
1
0.1
0.01
1 2 4 8 16 32
Days after treatment

FIG. 20


Post-exposure comparison of RVNA cocktail and HRIG, with vaccine, in Syrian hamsters
Percent survival
100
80
60
40
20
0
0
4
8
12
16
20
24
28
Days
1000 IU/kg RVNA + Vac.
500 IU/kg RVNA + Vac.
200 IU/kg RVNA + Vac.
20 IU/kg HRIG + Vac.
Vac.
Control